Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading hours on Thursday. $59.43 million flowed into the stock on the tick-up and $132.39 million flowed out of the stock on the tick-down, for a money net flow of $72.96 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $2.22 for the day and closed at $123.34

Several equities research analysts have recently issued reports on the stock. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 17th. Leerink Swann reiterated a “buy” rating and set a $216.00 price target (down previously from $217.00) on shares of Alexion Pharmaceuticals in a research note on Saturday, March 19th. BMO Capital Markets downgraded shares of Alexion Pharmaceuticals to a “buy” rating in a research note on Saturday, April 30th. Morgan Stanley reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Saturday, April 30th. Finally, Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Eight investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $193.07.

The stock has a market cap of $27.87 billion and a PE ratio of 188.23. The stock’s 50 day moving average is $132.82 and its 200 day moving average is $145.76.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.13 by $0.02. During the same period in the prior year, the company earned $1.28 earnings per share. The firm earned $701 million during the quarter, compared to analysts’ expectations of $710.98 million. The business’s quarterly revenue was up 16.8% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals Inc. will post $5.06 EPS for the current year.

In related news, EVP John B. Moriarty sold 918 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Martin Mackay sold 4,097 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $139.20, for a total value of $570,302.40. Following the transaction, the executive vice president now directly owns 42,706 shares of the company’s stock, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

A number of hedge funds have modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 12,973,958 shares of the biopharmaceutical company’s stock valued at $2,474,783,000 after buying an additional 252,272 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Alexion Pharmaceuticals by 7.0% in the fourth quarter. Jennison Associates LLC now owns 7,346,024 shares of the biopharmaceutical company’s stock valued at $1,401,254,000 after buying an additional 481,031 shares in the last quarter. Brown Advisory Inc. increased its stake in shares of Alexion Pharmaceuticals by 17.7% in the fourth quarter. Brown Advisory Inc. now owns 2,233,531 shares of the biopharmaceutical company’s stock valued at $426,046,000 after buying an additional 335,663 shares in the last quarter. Calamos Advisors LLC increased its stake in shares of Alexion Pharmaceuticals by 58.7% in the fourth quarter. Calamos Advisors LLC now owns 523,184 shares of the biopharmaceutical company’s stock valued at $99,797,000 after buying an additional 193,450 shares in the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. increased its stake in shares of Alexion Pharmaceuticals by 2.4% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 341,934 shares of the biopharmaceutical company’s stock valued at $65,415,000 after buying an additional 7,860 shares in the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.